Rok Herman still remembers the moment the PET/CT scans came back: 64.7% of women in the trial showed active brown fat after 24 weeks on tirzepatide—a tissue once thought dormant in adults and nearly invisible in people with obesity. Until now, the remarkable weight loss seen with drugs like tirzepatide was chalked up to appetite suppression. But the TABFAT trial, presented at ENDO 2026 in Chicago, reveals a deeper mechanism at play: the drug may be rewiring how the body burns energy itself.
This discovery matters because it shifts the paradigm of obesity treatment. For decades, the focus has been on intake—how to help people eat less. But what if the body could be prompted to burn more? Brown adipose tissue, or brown fat, is a metabolic furnace. Unlike white fat, which stores energy, brown fat burns calories to generate heat, especially in cold environments. It was long believed to vanish after infancy, but imaging advances in the late 2000s confirmed its presence in adults—though its activity is markedly suppressed in obesity. The strongest known activator until now? Moderate cold exposure. Tirzepatide, originally developed for type 2 diabetes, may now join—and surpass—that list.
Led by Dr. Rok Herman of the University Medical Center Ljubljana in Slovenia, the randomized, placebo-controlled trial focused on premenopausal women with obesity. Using cold-stimulated PET/CT imaging and MRI scans, the team measured brown fat activity before and after treatment. The results were striking: tirzepatide increased detectable brown adipose tissue activity from 41.2% to 64.7% of participants, with no significant change in the placebo group. Beyond activation, the drug also showed early signs of “browning” white subcutaneous fat—transforming energy-storing tissue into metabolically active “beige” fat. The consistency across multiple imaging modalities strengthened the findings, suggesting this isn’t a fluke, but a real biological shift.
The implications ripple beyond weight loss. If tirzepatide boosts energy expenditure at the tissue level, it opens the door to a new class of therapies that don’t just curb hunger but actively enhance metabolism. “They are not only appetite suppressants—tirzepatide also appears to modulate energy expenditure at the tissue level,” Herman said, envisioning future treatments that combine appetite regulation with thermogenic activation. Researchers now call for deeper exploration into harnessing brown and beige fat as a targeted strategy in obesity care—one that could personalize treatment based on metabolic profile rather than one-size-fits-all approaches.
As science begins to decode the body’s hidden metabolic engines, the future of obesity therapy may not lie in eating less, but in burning smarter.